View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
May 12, 2022

Strata Oncology enrols first patient in study of cancer therapies

The trial will leverage quantitative RNA and algorithms to deliver treatment selection for all therapeutic modalities.

Strata Oncology has enrolled the first patient in a prospective pan-tumour therapeutic clinical trial of several cancer therapies in new, biomarker-guided patient groups.

The Strata Precision Indications for Approved THerapies (Strata PATH) trial will evaluate the safety and efficacy of cancer therapies which are approved by the US Food and Drug Administration (FDA) in oncology.

All these therapies showed safety profiles in the advanced setting.

In the trial, each therapy will be administered according to the dosing regimen approved by the FDA.

The Strata PATH trial will deliver treatment selection for all therapeutic modalities by leveraging the company’s new quantitative RNA and multivariate algorithms.

Strata Oncology co-founder and CEO Dan Rhodes said: “The Strata PATH trial is a crucial step in our mission to accelerate the impact of precision medicine for patients with cancer, in both the early-stage and late-stage settings.

“There is no time to spare when it comes to getting patients their best possible therapies, so we have taken the initiative to sponsor this trial to prospectively test novel biomarker-guided treatment hypotheses that we believe may result in new, highly-responsive pan-tumor molecular indications for FDA-approved therapies.”

The first patient for the trial has been enrolled at the Kettering Health site.

For devising the hypotheses, which is being tested in the latest trial, Strata used its clinical molecular database developed through the previous Strata Trial.

This database comprises DNA mutation profiles as well as quantitative RNA expression data.

For the Strata PATH trial, patients with advanced cancer and early-stage cancer with evidence of micrometastatic disease following initial treatment, will be enrolled.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU